1. Introduction
Recently, receptor-targeted α-therapy (TAT) has gained importance in nuclear medicine clinical routine, especially for tumor patients who develop resistance to β
–-therapy [
1,
2]. Typically, patients receive multiple doses of
90Y or
177Lu (dose of 5–8 GBq per patient) at periodic intervals of administration (e.g., 8-week intervals) [
3]. Unfortunately, a significant proportion of these patients will eventually experience progressive disease and discontinue therapy. On the other hand, it has been observed that further responses and prolonged survival can be achieved by initiating α-therapy after disease progression. For example, the use of
225Ac (dose: 100 kBq/kg, four α-particles per decay) can dramatically reduce the required level of administered radioactivity (by a factor of about 1000 compared to
177Lu). However, the behavior of α-particles in tumor cells is complicated by α-emitting radionuclide progeny in the
225Ac series. Of particular interest are
221Fr,
217At,
213Bi, and
213Po. A key issue is the biological fate of
213Bi (t
1/2 46 min), which is transported out of the tumor cells (by its own escape or by the escape of
221Fr or
217At) and accumulates mainly in the kidneys, delivering an α-emitting dose of
213Po, which, in turn, could have a higher negative impact on renal function [
4]. Therefore, it is often suggested that only patients with an efficient renal function can be considered eligible for
225Ac therapy, while patients with impaired renal function may not be eligible for these therapies.
212Pb is a promising radionuclide for targeted alpha particle therapy that emits only one α-particle per β
–-decay of
212Pb to
212Bi and then either 64% to
212Po or 36% to
208Tl [
5,
6]. Therefore, a
212Pb-labeled radiopharmaceutical, once accumulated in the tumor tissue, will deposit its highest dose in the form of the α-particle specifically in the tumor cells, with a lower probability of further α-decay occurring in healthy organs. Thus,
212Pb represents a more favorable choice for cancer α-therapy patients who are naïve to (or who have progressed on) β
–-therapy, including patients with reduced renal function. Ongoing preclinical and clinical studies are investigating the potential of
212Pb-labeled peptides and antibodies (at a dose of approximately 2 MBq/kg) [
4] or approximately between
177Lu and
225Ac administered doses of radioactivity. Lead specific chelator-PEG
2-[Tyr
3,Thr
8]-octreotide (PSC-PEG
2-TOC) (VMT-α-NET) is a somatostatin subtype 2 (SST2) receptor targeting peptide for the treatment of neuroendocrine tumors (NETs) that exhibits rapid tumor accumulation, high tumor retention, and rapid renal excretion [
7]. It carries the chelator PSC [
7], which forms highly stable complexes with
203/212Pb and, in contrast to less stable 1,4,7,10-tetraazacyclododecane-
N,
N′,
N″,
N‴-tetraacetic acid (DOTA) complexes, remains intact even after β
– conversion to
212Bi [
8]. Recently, the true matched pair
203/212Pb has come into focus through several first in-human theranostic applications [
9,
10,
11]. While
203Pb (t
1/2 = 52 h; 279 keV gamma ray; 81% intensity) represents an ideal elementally matched imaging surrogate,
212Pb itself can be used for SPECT imaging [
12]. A true matched pair could finally overcome the differential pharmacokinetic/pharmacological properties observed between diagnostic and therapeutic radiotracers with unmatched radionuclides pairs [
13].
In addition to somatostatin analogs, such as PSC-TOC, other radiopharmaceuticals targeting other receptors (e.g., PSMA derivatives) for radiolabeling with
203/212Pb are under preclinical investigation and may soon be translated into clinical use [
4,
14,
15,
16]. Emerging evidence suggests that α-particles have the potential to overcome resistance to β
–-therapy and could lead to further therapeutic options for patients with palliative effects and, in some cases, even complete remission [
17]. Furthermore, the appearance of Cherenkov light due to the decay of
212Pb may be useful not only for diagnostics but also for further treatment options [
18]. The optimal mass of the precursor peptide for radiopharmaceuticals is an important parameter in radiopharmaceutical development to ensure that the highest degree of tumor targeting with the lowest accumulation and retention in normal organs and healthy tissues is achieved. This parameter is also important in achieving a formulation that results in smooth radiometallation and a high radiochemical yield and purity. In general, this parameter is known as the molar activity (A
M), which plays a crucial role for all PET radiotracers targeting saturable binding sites (e.g., receptors) but is secondary or negligible for many metabolic PET radiotracers, where the endogenous levels of the compound are in great excess of the radiotracer itself due to saturation of the receptors at the tumor site [
19].
In this work, the influence of the AM-to-cell uptake of 203/212Pb-PSC-TOC was investigated in different cell lines (AR42 J, HEK293 sst2, and ZR75-1) to develop a more detailed understanding of the tracer in preparation for clinical use.
4. Materials and Methods
All reagents and solvents were purchased from commercial suppliers at the highest purity and used without further purification. PSC-PEG2-TOC (VMT-α-NET) and 224Ra/212Pb generator (VMT-α-GEN) were obtained from Perspective Therapeutics Inc., Coralville, IA, USA. 203Pb solution in 8 M HCl was obtained from Cross Cancer Institute, Edmonton, AB, Canada. RCP was monitored by thin-layer chromatography (TLC) on iTLC-SG plates (Agilent, Santa Clara, CA, USA). Measurement of the radionuclide purity (RNP) and evaluation of the radio-TLC was performed with a thin-layer scanner (MiniScanPRO+, Eckert&Ziegler Eurotope GmbH, Berlin, Germany) equipped with a Model 43-2 alpha detector ZnS(Ag) scintillator (Ludlum Measurements, Sweetwater, TX, USA) and a build-in multi-channel analyzer (MCA) for gamma spectroscopy. Radio-HPLC was performed on a Shimadzu HPLC system (Thermo Scientific, Dreieich, Germany), equipped with a reverse-phase column (Merck Chromolith RP-18e; 100 × 4.6 mm plus a 5 × 4.6 mm guard column, Darmstadt, Germany) and a UV diode array detector (220 nm). The solvent system used was a gradient of acetonitrile:water (containing 0.05% TFA) (0–13 min: 0–60% MeCN) at a flow rate of 1.6 mL/min, unless otherwise stated. The pH was measured using a reflectance photometer (QUANTOFIX Relax, Macherey-Nagel GmbH & Co. KG, Düren, Germany).
4.1. Radiochemistry
Radiolabeling of the DOTA and PSC conjugates was performed according to standard protocols for these chelators [
7]. Briefly, 50 µg precursor (DOTA-TATE (M = 1435.6 g/mol) or PSC-PEG
2-TOC (PSC-PEG
2-TOC, M = 1578.7 g/mol)) in H
2 O
suprapure was added to a 10 mL reaction vial together with 100 µL EtOH
absolute, 290 µL 1 M NaAc/AcOH buffer (pH 4, 99.99% trace metal), and 2 mg sodium ascorbate (Ph.Eur.).
203/212Pb in 5–10 mL 1.6 M HClsuprapure was trapped on a custom-made Pb resin cartridge (100 mg PB-B10-F, Triskem, Bruz, France) preconditioned with 1 mL 2 M HClsuprapure. The captured activity was rinsed with 1 mL 2 M HClsuprapure. The activity was eluted with 2 mL NaAc/AcOH buffer (pH 6, 99.99% trace metal) directly into the reaction vial. The solution was heated at 95 °C for 15 min for 203Pb and 15 or 45 min for 212Pb. The reaction solution was then diluted with 4 mL of 0.9% NaCl solution and cooled.
Finally, the product was purified by using a C18 Plus light cartridge (WAT023501, Waters, Eschborn, Germany) preconditioned with 1 mL EtOH and 3 mL H2 O (wet condition). The cooled and diluted product solution (4 mL 0.9% NaCl) was slowly passed through the C18 cartridge. The C18 cartridge containing the product was rinsed with 2 mL of 0.9% NaCl solution and was directly eluted with 1 mL of 50% EtOH for injection directly through a vented sterile filter (0.22 µm, SLGVV255F, Millex-GV, Merck-Millipore, Darmstadt, Germany) into a product vial. Finally, the product was diluted with 7 mL of 0.9% NaCl solution.
Another purification method was performed using a Maxi-Clean (MC) SPE 0.5 mL IC-Chelate cartridge (5122565, S*Pure, Mainz, Germany) preconditioned with 5 mL H2 Osuprapure (wet condition). The cooled and diluted product solution (4 mL 0.9% NaCl) was slowly transferred through a vented sterile filter into the product vial via the MC cartridge and washed with an additional 2 mL 0.9% NaCl into the product vial.
4.2. Quality Control of Radiotracer
Quality control included several standard tests established in the clinical manufacturing:
4.3. Cell Uptake Experiments
Cell uptake of 203/212Pb-PSC-TOC was tested against our gold standard 68Ga-DOTATATE. AR42J (CRL-1492, ATCC®, Manassas, VA, USA), HEK293 sst2 (stably SST2 receptor transfected cells derived from Andrea Kliewer, University Hospital, Jena, Germany), and ZR75-1 (CRL-1500, ATCC®, Manassas, VA, USA); cells were seeded 1–2 days prior to the assay in 6-well plates to reach 0.5 × 106 cells per well in a humidified atmosphere containing 5% CO2.
Each cell line was grown in its own medium:
AR42J: Gibco RPMI 1640 medium (ATCC-Modification) supplemented with 10% fetal calf serum (FCS)
HEK293 sst2 (stably transfected HEK293 cells): Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum (FCS), l-glutamine (2 mM = 1%), G-418 (50 mg/mL)
ZR75-1: Gibco RPMI 1640 medium (w/o glutamine) supplemented with 10% fetal calf serum (FCS), 1% NEAA, 1 mM sodium pyruvate (1%), and 2 mM N-acetyl-alanyl-l-glutamine (1%)
After incubation with the respective radiotracer for 1 h, 24 h, 48 h, and 72 h, the medium, wash fraction (2 × 1 mL cold PBS 4 °C), and cell fraction (lysed with 1 mL 0.1 M NaOH and cell scraper) were collected, and the remaining activity in the fractions was measured with a gamma counter (HIDEX). The relative cell uptake in percent per 1 million cells was calculated between the medium, wash fraction, and lysate. Each cell incubation was performed in triplicate.
5. Conclusions
It was shown that the AM of 203/212Pb-PSC-TOC has an effect on the cell uptake. No saturation was found in this work, but it is known from the literature that higher AM > 100 MBq/nmol could have a negative effect on tumor uptake due to non-specific binding of the radioligand. It is noteworthy that higher AM leads to higher cell uptake due to receptor-specific binding, and the values found in this work can be used as a reference for clinical application.
Another interesting radiochemical observation of this investigation is that the 212Pb labeling benefited from a longer reaction time and a larger amount of precursor to achieve a high RCY. Since 203Pb and 212Pb are elementally identical, the apparent differences must necessarily be due to the differences in stable Pb found in the solutions provided (generator eluant versus 203Pb solution), and thus, further investigation of the relative specific activity of the solutions is required.
In conclusion, for high tumor uptake, radiolabeling of 50 µg of PSC-TOC precursor should be performed with >1000 MBq 203Pb and with >500 MBq 212Pb.